Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 1999

View Archived Issues

Sibia Neurosciences and Lilly enter collaboration for CNS disorders

Canadian university spins off new company to develop promising antibacterial agents

PathoGenesis signs European distribution agreements and launches TOBI in two new markets

NIAID-sponsored scientists on the way to developing a broad-spectrum staph vaccine

New perspectives for rFVIIa and rFVIIai

Remicade recommended for European approval by CPMP

Lamivudine to be launched in South Korea for hepatitis B

Phase II trial of York Medical's cancer vaccine cleared

Palatin Technologies prepares BLA for imaging agent

Additional phase II data suggest modifications for AVI BioPharma's cancer vaccine

Chinese scientists present new antiarrhythmic agent and effects on ischemia/reperfusion injury

Chinese scientists discover new MDR reversal agents during search for cardiovascular agents

New cholesterol-binding agent on the road to launch in Japan

Daiichi Pharmaceutical will market cevimeline in the U.S.

Chinese herbal remedy is safer and more effective than sildenafil in treating ED

Company Profile: ProtoMed

Carbapenems from Merck especially useful against resistant bacteria

Pfizer researchers present selective inhibitors of urokinase and their use

More on protein farnesyltransferase inhibitors in development at Merck

5-HT1A receptor agonists with good potency and selectivity designed at Pierre Fabre

Small study indicates therapeutic potential of sildenafil in women with sexual arousal disorders

Imidazole-based protein farnesyltransferase inhibitors for cancer

Novel class III antiarrhythmic agents synthesized at Merck

Novel matrix metalloproteinase inhibitor selectively inhibits rat osteosarcoma lung metastasis

Pharmacia & Upjohn's new treatment for ED in phase II testing; clinical results presented at AUA

Radiolabeled somatostatin analogue with potential for PET imaging and targeted radiotherapy

CGRP gene transfer successful and effective in rat model of pulmonary hypertension

Plant-derived compounds significantly reduce BP in hypertensive patients, SHRs

Hughes Institute publishes findings on anti-HIV agent active against resistant virus strains

Resubmission of ProMem NDA announced by Bayer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...